Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Anthony S. Marucci Purchases 11,500 Shares of Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Anthony S. Marucci purchased 11,500 shares of Celldex Therapeutics stock in a transaction dated Monday, November 11th. The stock was bought at an average price of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Celldex Therapeutics Trading Up 3.1 %

Shares of CLDX stock opened at $27.01 on Wednesday. The company has a fifty day moving average price of $33.29 and a two-hundred day moving average price of $35.72. Celldex Therapeutics, Inc. has a one year low of $24.43 and a one year high of $53.18.

Wall Street Analyst Weigh In

CLDX has been the subject of several research analyst reports. The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, November 7th. Citigroup initiated coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 target price for the company. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Institutional Trading of Celldex Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its stake in Celldex Therapeutics by 2.0% in the second quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock valued at $601,000 after acquiring an additional 325 shares during the last quarter. KBC Group NV lifted its stake in Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 495 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in Celldex Therapeutics by 9.5% in the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 638 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Celldex Therapeutics by 23.7% in the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after acquiring an additional 1,504 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.